GlaxoSmithKline Plc.

GlaxoSmithKline (GSK) is the world’s third largest pharmaceutical company. Its product range covers all the major illnesses that we suffer from, including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions. Diabetes medication is increasing in demand as more people develop obesity related illnesses.

A Brief History of GlaxoSmithKline

GlaxoSmithKline is the result of several mergers. In 1880 Burroughs Wellcome & Company was formed in London and then in 1904 Glaxo was founded in New Zealand. In 1995 Burroughs Wellcome and Glaxo merged to form GlaxoWellcome.

In 1843 Thomas Beecham developed and marketed laxatives and founded the Beecham Group. In 1830 a John K. Smith started out in pharmaceuticals in Philadelphia. He was joined by Mahlon Kline in 1865 and in 1875 the business was renamed Smith, Kline & Co. In 1891 it merged with French, Richard and Company and became Smith Kline & French Laboratories. In 1963 it decided to focus on vaccinations and after more mergers became SmithKline Beckman in 1982.

In 1988 SmithKline Beckman bought International Clinical Laboratories and then the following year it merged with Beecham to become SmithKline Beecham plc. after moving its headquarters to the UK.

In 2000 Glaxo Wellcome and SmithKline Beecham merged to become GlaxoSmithKline. This was once of the biggest corporate actions mergers of all time.

Terms of the Glaxo Wellcome Merger

The terms of the merger were one new GlaxoSmithKline share for each Glaxo Wellcome share held and 0.4552 GlaxoSmithKline shares for each SmithKline Beecham share. The effective date was 27th December, 2000.

Glaxo Share Prices

See all the latest prices on Google Finance:

Company Information

  • GlaxoSmithKline plc
  • 980 Great West Road
  • Brentford
  • Middlesex TW8 9GS
  • Tel: +44 (0)20 8047 5000
  • Fax: +44 (0)20 8047 7807
  • Website:

Company Registrar

  • Equiniti Limited
  • Aspect House
  • Spencer Road
  • Lancing
  • West Sussex BN99 6DA
  • Shareholder Portal:

GlaxoSmithKline Dividend Payments

GKN pays a dividend each quarter, generally paying at the beginning of January, April, July and October. The dividen payment is split evenly throughout the year.

Historic annual dividends:

  • 2004 = 43p
  • 2005 = 42p
  • 2006 = 46p
  • 2007 = 50p
  • 2008 = 55p
  • 2009 = 61p
  • 2010 = 65p

More shareholder information available on the Glaxo investors portal:

  17 comments for “GlaxoSmithKline Plc.

  1. SHP
    July 16, 2013 at 10:47 am

    “GlaxoSmithKline Plc (GSK)’s sales in China jumped 20 percent to about 1 billion pounds ($1.5 billion) last year, almost quadruple the pace of growth across its emerging markets. Police say bribes and sexual favors spurred the gain.”

    Full story:

  2. SHP
    July 3, 2012 at 12:17 pm

    GlaxoSmithKline (GSK) is to pay $3bn (£1.9bn) in the largest healthcare fraud settlement in US history. – From the BBC:

  3. SHP
    June 13, 2011 at 5:54 pm

    GlaxoSmithKline’s new epilepsy drug, Potiga, has been approved by US regulators. GSK has developed Potiga in partnership with Canada’s Valeant.

  4. SHP
    June 9, 2011 at 5:41 pm

    Taiwan hospitals have stopped the administration of the GlaxoSmithKline’s antibiotic Augmentin over plasticizer contamination concerns. News source:

  5. SHP
    June 6, 2011 at 9:19 am

    GlaxoSmithKline announced today that they are lowering prices in the developed world to make their #medicine more accessible to poorer populations. The main drug is the #Rotarix vaccine which causes diarrhoea and kills many children each year. Andrew Witty (CEO) said: “I hope this will enable millions of children to receive this important vaccine, saving countless lives in the future.”

  6. SHP
    June 1, 2011 at 5:17 pm

    GlaxoSmithKline is currently analysing the data from a study of its h1N1 vaccine Pandemrix after 247 cases of narcolepsy in patients who had taken the medicine.

  7. SHP
    May 31, 2011 at 11:45 am

    #Lucozade Sport is being re-branded. GSK is updating both the packaging and the contents of the sports drinks. Lucazade is one of the most popular isotonic / carbohydrate sports drinks and is marketed globally.

  8. SHP
    May 29, 2011 at 8:55 am

    Glaxo has reported that it has increased its business in the emerging markets by around 20% which is helping to recover lost sales due to more generic drugs coming to market. 33% of Glaxo’s sales are now in the emerging markets.

  9. SHP
    May 26, 2011 at 6:28 pm

    GlaxoSmithKline’s RTS,S Malaria vaccine is going through its 3rd trial in Africa today.
    If this drug passes the tests it could provide malaria relief for millions of people for many years to come.

  10. SHP
    May 26, 2011 at 4:08 pm

    The U.S. Food and Drug Administration (FDA) has approved the first generic version of Combivir (lamivudine/zidovudine) which is an anti-HIV medication. The drug will be made by Teva Pharmaceuticals. The branded drug Combivir is marketed by ViiV Healthcare, a joint venture of GlaxoSmithKline and Pfizer.

  11. SHP
    May 26, 2011 at 1:12 pm

    GlaxoSmithKline plc is selling off large parts of its is non-prescription products. The most well known product they currently own is the weight-loss drug Alli. As the moment we do not know who the buyer for Alli is.

  12. SHP
    May 25, 2011 at 9:45 am

    1st Quarter dividend payment for 2011 is 16p, ex-date was 04/05/2011, pays on 07/07/2011.

  13. SHP
    May 25, 2011 at 12:55 am

    “The pharma giant has announced that 20% of last year’s profit from least developed countries will be reinvested in healthcare in those areas – to pay for the recruitment, training and retention of healthcare workers.” Source:

  14. SHP
    May 25, 2011 at 12:52 am

    Vardenafil HCI (Staxyn, GlaxoSmithKline, Merck, and Bayer), an orally disintegrating tablet indicated for the treatment of erectile dysfunction (ED) in men, is now available in U.S. pharmacies. It is the first and only orally disintegrating tablet to treat ED. Staxyn was FDA approved in June 2010.

    Could bolster Glaxo shares if this product proves popular.

  15. SHP
    May 23, 2011 at 9:15 pm

    Update on GlaxoSmithKline PLC (GSK.LN). Glaxo has bought 500,000 of its ordinary shares. It paid 1311.50 – 1321.50p per share. Overall trade saw a fall of 1.35% to a share price of GBP13.15. Glaxo is currently valued at GBP67.87 billion.

  16. CityAnalyst
    May 22, 2011 at 9:15 pm

    Althought Glaxo is on a high still says “TheStreet Ratings rates GlaxoSmithKline as a hold.” Read their full report here:

  17. SHP
    May 20, 2011 at 5:24 pm

    GlaxoSmithKline PLC (GSK) finished the week on a high closing at 1,333.65p. today says that Glaxo is “showing bullish tecnhicals” with a 4.89% dividend yield.

    The next quarterly dividend payment pays 16p per share on 7th July 2011. Ex-date was 4th May 2011.

    If you invest now you will be eligible for the next dividend payment which is due to pay around the 7th October 2011. Ex-date is likely to be around 28th July 2011 so you will need to invest by then. Check with your broker to be sure.

Leave a Reply

Your email address will not be published. Required fields are marked *